Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines

Human Gene Therapy

Volumn 28, Issue 4, 2017, Pages 350-360

  Kotin, Robert M ^a   Snyder, Richard O ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Brammer Bio LLC   (United States)

Author keywords

AAV vector; Sf9 cells

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3;

ADENO ASSOCIATED VIRUS; ARTICLE; BACULOVIRIDAE; DNA REPLICATION; DNA SYNTHESIS; GENE AMPLIFICATION; GENE TRANSFER; INVERTEBRATE; INVERTED TERMINAL REPEAT; NONHUMAN; OPEN READING FRAME; PARVOVIRIDAE; PROMOTER REGION; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; SF9 CELL LINE; START CODON; VIRAL GENE THERAPY; VIRUS CELL INTERACTION; VIRUS RECOMBINANT; ANIMAL; BIOSYNTHESIS; CELL LINE; CYTOLOGY; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; PROCEDURES; THERAPEUTIC USE;

ANIMALS; CELL LINE; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INVERTEBRATES;

EID: 85018473420     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2017.042     Document Type: Article

References (92)

1. Flotte TR, Trapnell BC, Humphries M, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 2011;22:1239-1247.
2. Gaudet D, Methot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipidol 2012;23:310-320.
3. High KH, Nathwani A, Spencer T, et al. Current status of haemophilia gene therapy. Haemophilia 2014;20:43-49.
4. Spencer HT, Riley BE, Doering CB. State of the art: gene therapy of haemophilia. Haemophilia 2016; 22:66-71.
5. Bennett J, Wellman J, Marshall KA, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet 2016; 388:661-672.
6. Pierce EA, Bennett J. The status of RPE65 gene therapy trials: safety and efficacy. Cold Spring Harb Perspect Med 2015;5:a017285.
7. Feuer WJ, Schiffman JC, Davis JL, et al. Gene therapy for Leber hereditary optic neuropathy: initial results. Ophthalmology 2016;123:558-570.
8. McIntosh JH, Cochrane M, Cobbold S, et al. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAVmediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Ther 2012;19:78-85.
9. European Medicines Agency. Glybera (alipogene tiparvovec). www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002145/human-med-001480.jsp&mid=WC0b01ac058001d124 (last accessed June 15, 2016).
10. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005;5:285-297.
11. Grimm D, Lee JS, Wang L, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adenoassociated viruses. J Virol 2008;82:5887-5911.
12. Gray SJ, Blake BL, Criswell HE, et al. Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther 2010;18:570-578.
13. Yang L, Li J, Xiao X. Directed evolution of adenoassociated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol 2011;709:127-139.
14. Grimm D, Zolotukhin S. E pluribus unum: 50 years of research, millions of viruses, and one goal - tailored acceleration of AAV evolution. Mol Ther 2015;23:1819-1831.
15. Petrs-Silva H, Dinculescu A, Li Q, et al. Highefficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009;17:463-471.
16. Jayandharan GR, Zhong L, Sack BK, et al. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses. Hum Gene Ther 2010;21:271-283.
17. Li M, Jayandharan GR, Li B, et al. High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum Gene Ther 2010;21:1527-1543.
18. Qiao C, Zhang W, Yuan Z, et al. Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther 2010;21:1343-1348.
19. Cheng B, Ling C, Dai Y, et al. Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Ther 2012;19:375-384.
20. Redemann BE, Mendelson E, Carter BJ. Adenoassociated virus rep protein synthesis during productive infection. J Virol 1989;63:873-882.
21. Ward P, Urcelay E, Kotin R, et al. Adenoassociated virus DNA replication in vitro: activation by a maltose binding protein/Rep 68 fusion protein. J Virol 1994;68:6029-6037.
22. Smith RH, Kotin RM. The Rep52 gene product of adeno-associated virus is a DNA helicase with 3′-to-5′ polarity. J Virol 1998;72:4874-4881.
23. Im DS, Muzyczka N. The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell 1990;61:447-457.
24. Wonderling RS, Kyostio SR, Owens RA. A maltose-binding protein/adeno-associated virus Rep68 fusion protein has DNA-RNA helicase and ATPase activities. J Virol 1995;69:3542-3548.
25. Zhou X, Zolotukhin I, Im DS, et al. Biochemical characterization of adeno-associated virus rep68 DNA helicase and ATPase activities. J Virol 1999; 73:1580-1590.
26. Ilyina TV, Koonin EV. Conserved sequence motifs in the initiator proteins for rolling circle DNA replication encoded by diverse replicons from eubacteria, eucaryotes and archaebacteria. Nucleic Acids Res 1992;20:3279-3285.
27. McCarty DM, Ryan JH, Zolotukhin S, et al. Interaction of the adeno-associated virus Rep protein with a sequence within the A palindrome of the viral terminal repeat. J Virol 1994;68:4998-5006.
28. Snyder RO, Im DS, Muzyczka N. Evidence for covalent attachment of the adeno-associated virus (AAV) rep protein to the ends of the AAV genome. J Virol 1990;64:6204-6213.
29. Zimmermann B, Chiorini JA, Ma Y, et al. PrKX is a novel catalytic subunit of the cAMP-dependent protein kinase regulated by the regulatory subunit type I. J Biol Chem 1999;274:5370-5378.
30. Schmidt M, Chiorini JA, Afione S, et al. Adenoassociated virus type 2 Rep78 inhibition of PKA and PRKX: fine mapping and analysis of mechanism. J Virol 2002;76:1033-1042.
31. Chiorini JA, Zimmermann B, Yang L, et al. Inhibition of PrKX, a novel protein kinase, and the cyclic AMP-dependent protein kinase PKA by the regulatory proteins of adeno-associated virus type 2. Mol Cell Biol 1998;18:5921-5929.
32. Xie Q, Bu W, Bhatia S, et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A 2002;99:10405-10410.
33. Marcus CJ, Laughlin CA, Carter BJ. Adenoassociated virus RNA transcription in vivo. Eur J Biochem 1981;121:147-154.
34. Becerra SP, Rose JA, Hardy M, et al. Direct mapping of adeno-associated virus capsid proteins B and C: a possible ACG initiation codon. Proc Natl Acad Sci U S A 1985;82:7919-7923.
35. Trempe JP, Carter BJ. Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein. J Virol 1988;62:3356-3363.
36. Zadori Z, Szelei J, Lacoste MC, et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001;1:291-302.
37. Girod A, Wobus CE, Zadori Z, et al. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol 2002;83:973-978.
38. Sonntag F, Kother K, Schmidt K, et al. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J Virol 2011;85:12686-12697.
39. Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A 2010; 107:10220-10225.
40. Earley LF, Powers JM, Adachi K, et al. Adenoassociated virus (AAV) assembly-activating protein is not an essential requirement for capsid assembly of AAV serotypes 4, 5, and 11. J Virol 2017;91.
41. Chiorini JA, Wiener SM, Owens RA, et al. Sequence requirements for stable binding and function of Rep68 on the adeno-associated virus type 2 inverted terminal repeats. J Virol 1994;68: 7448-7457.
42. Chiorini JA, Yang L, Safer B, et al. Determination of adeno-associated virus Rep68 and Rep78 binding sites by random sequence oligonucleotide selection. J Virol 1995;69:7334-7338.
43. Hickman AB, Ronning DR, Perez ZN, et al. The nuclease domain of adeno-associated virus rep coordinates replication initiation using two distinct DNA recognition interfaces. Mol Cell 2004;13:403-414.
44. Smith RH, Spano AJ, Kotin RM. The Rep78 gene product of adeno-associated virus (AAV) selfassociates to form a hexameric complex in the presence of AAV ori sequences. J Virol 1997;71: 4461-4471.
45. Brister JR, Muzyczka N. Rep-mediated nicking of the adeno-associated virus origin requires two biochemical activities, DNA helicase activity and transesterification. J Virol 1999;73:9325-9336.
46. Brister JR, Muzyczka N. Mechanism of Repmediated adeno-associated virus origin nicking. J Virol 2000;74:7762-7771.
47. Smith RH, Kotin RM. An adeno-associated virus (AAV) initiator protein, Rep78, catalyzes the cleavage and ligation of single-stranded AAV ori DNA. J Virol 2000;74:3122-3129.
48. Snyder RO, Samulski RJ, Muzyczka N. In vitro resolution of covalently joined AAV chromosome ends. Cell 1990;60:105-113.
49. Kotin RM, Berns KI. Organization of adenoassociated virus DNA in latently infected Detroit 6 cells. Virology 1989;170:460-467.
50. Kotin RM, Siniscalco M, Samulski RJ, et al. Sitespecific integration by adeno-associated virus. Proc Natl Acad Sci U S A 1990;87:2211-2215.
51. Myers MW, Laughlin CA, Jay FT, et al. Adenovirus helper function for growth of adeno-associated virus: effect of temperature-sensitive mutations in adenovirus early gene region 2. J Virol 1980;35: 65-75.
52. Stutika C, Huser D, Weger S, et al. Definition of herpes simplex virus helper functions for the replication of adeno-associated virus type 5. J Gen Virol 2015;96:840-850.
53. Weindler FW, Heilbronn R. A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol 1991;65:2476-2483.
54. Cao M, Zhu H, Bandyopadhyay S, et al. HPV-16 E1, E2 and E6 each complement the Ad5 helper gene set, increasing rAAV2 and wt AAV2 production. Gene Ther 2012;19:418-424.
55. Wright JF. Transient transfection methods for clinical adeno-associated viral vector production. Hum Gene Ther 2009;20:698-706.
56. Liu XL, Clark KR, Johnson PR. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus. Gene Ther 1999;6:293-299.
57. Schnepp BC, Jensen RL, Clark KR, et al. Infectious molecular clones of adeno-associated virus isolated directly from human tissues. J Virol 2009; 83:1456-1464.
58. Conway JE, Rhys CM, Zolotukhin I, et al. Hightiter recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther 1999;6:986-993.
59. Grimm D, Kern A, Rittner K, et al. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998;9:2745-2760.
60. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72: 2224-2232.
61. Chejanovsky N, Carter BJ. Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication. Virology 1989;173:120-128.
62. King JA, Dubielzig R, Grimm D, et al. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J 2001;20:3282-3291.
63. Cotmore SF, Agbandje-McKenna M, Chiorini JA, et al. The family Parvoviridae. Arch Virol 2014; 159:1239-1247.
64. Ding C, Urabe M, Bergoin M et al. Biochemical characterization of Junonia coenia densovirus nonstructural protein NS-1. J Virol 2002;76:338-345.
65. Thompson CM, Aucoin MG, Kamen AA. Production of virus-like particles for vaccination. Methods Mol Biol 2016;1350:299-315.
66. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002;13:1935-1943.
67. Negrete A, Yang LC, Mendez AF, et al. Economized large-scale production of high yield of rAAV for gene therapy applications exploiting baculovirus expression system. J Gene Med 2007;9:938-948.
68. Smith RH, Levy JR, Kotin RM. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields hightiter rAAV stocks from insect cells. Mol Ther 2009; 17:1888-1896.
69. Cecchini S, Virag T, Kotin RM. Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02-to 200-liter cultures. Hum Gene Ther 2011;22:1021-1030.
70. Gray JT, Zolotukhin S. Design and construction of functional AAV vectors. Methods Mol Biol 2011; 807:25-46.
71. Kohlbrenner E, Aslanidi G, Nash K, et al. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol Ther 2005;12:1217-1225.
72. MietzschM, Casteleyn V,Weger S, et al. OneBac 2.0: Sf9 cell lines for production of AAV5 vectors with enhanced infectivity and minimal encapsidation of foreign DNA. Hum Gene Ther 2015;26:688-697.
73. Zolotukhin S. Direct head-to-head evaluation of rAAV vectors manufactured in human vs insect cells. ISBiotech 7th Spring Meeting, International Society for BioProcess Technology, Washington, DC, 2017.
74. Snyder RO, Audit M, Francis JD. rAAV vector product characterization and stability studies. In: RO Snyder and P Moullier, eds. Methods in Molecular Biology, Adeno-Associated Virus: Methods and Protocols. Totowa, NJ: Humana Press/Springer, 2011:405-428.
75. Adeno-Associated Virus Serotype 2 Reference Standard Material. Supported by the NGVL. American Type Culture Collection. www.atcc.org/Standards/Standards Programs/ATCC Virus Reference Materials/AAV2 Additional Information.aspx (last accessed XXX).
76. Lock M, McGorray S, Auricchio A, et al. Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther 2010;21:1273-1285.
77. Hamilton MA, Russo RC, Thurston RV. Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays. Environ Sci Technol 1977;11:714-719.
78. Karber G. Beitrag zur kollectiven Behanlung pharmakologischer Reihenversuche. Naunyn-Schmiedebergs. Arch Exp Pathol Pharmakol 1931; 162:480-483.
79. Spearman C. The method of "right and wrong cases" (constant stimuli) without Gauss's formula. Br J Psychol 1908;2:227-242.
80. Ayuso E. Comparative studies of AAV2 manufacturing: mammalian vs insect cells. ISBiotech 7th Spring Meeting, International Society for BioProcess Technology, Washington, DC, 2017.
81. Wasilko DJ, Lee SE, Stutzman-Engwall KJ, et al. The titerless infected-cells preservation and scale-up (TIPS) method for large-scale production of NO-sensitive human soluble guanylate cyclase (sGC) from insect cells infected with recombinant baculovirus. Protein Expr Purif 2009;65:122-132.
82. Ma H, Galvin TA, Glasner DR, et al. Identification of a novel rhabdovirus in Spodoptera frugiperda cell lines. J Virol 2014;88:6576-6585.
83. Maghodia AB, Geisler C, Jarvis DL. Characterization of an Sf-rhabdovirus-negative Spodoptera frugiperda cell line as an alternative host for recombinant protein production in the baculovirus-insect cell system. Protein Expr Purif 2016;122:45-55.
84. Ferrari FK, Samulski T, Shenk T, et al. Secondstrand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996;70:3227-3234.
85. Urabe M, Nakakura T, Xin KQ, et al. Scalable generation of high-titer recombinant adenoassociated virus type 5 in insect cells. J Virol 2006;80:1874-1885.
86. Martin J, Frederick A, Luo Y, et al. Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production. Hum Gene Ther Methods 2013;24: 253-269.
87. Schnodt M, Schmeer M, Kracher B, et al. DNA minicircle technology improves purity of adenoassociated viral vector preparations. Mol Ther Nucleic Acids 2016;5:e355.
88. Hong G, Ward P, Berns KI. In vitro replication of adeno-associated virus DNA. Proc Natl Acad Sci U S A 1992;89:4673-4677.
89. Ward P, Berns KI. In vitro rescue of an integrated hybrid adeno-associated virus/simian virus 40 genome. J Mol Biol 1991;218:791-804.
90. Hong G, Ward P, Berns KI. Intermediates of adeno-associated virus DNA replication in vitro. J Virol 1994;68:2011-2015.
91. Petrov AS, Harvey SC. Packaging double-helical DNA into viral capsids: structures, forces, and energetics. Biophys J 2008;95:497-502.
92. Clark KR. Recent advances in recombinant adenoassociated virus vector production. Kidney Int 2002; 61:S9-15.